Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment or prevention of urogenital atrophy and its symptoms in women

A technology for urinary symptoms and women, applied in the field of inhibiting female atrophy or treating or preventing symptoms related to female atrophy, can solve the problem of reducing the carcinogenicity of endometrial cancer, increasing the risk of endometrial cancer and breast cancer, and not reducing the risk of breast cancer cancer risk

Inactive Publication Date: 2009-04-15
HORMOS MEDICAL OY LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, estrogen can increase the risk of endometrial and breast cancer
Continuous progestin therapy can reduce the carcinogenicity of endometrial cancer, but progesterone does not reduce the risk of breast cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment or prevention of urogenital atrophy and its symptoms in women
  • Treatment or prevention of urogenital atrophy and its symptoms in women
  • Treatment or prevention of urogenital atrophy and its symptoms in women

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0028] experiment

[0029] Clinical phase I-II study to investigate the effect of ospemifene on endometrial thickness, endometrial pathology (biopsy according to curettage described by Vuopala et al., 1982) in healthy postmenopausal women volunteers aged 55 to 69 years and cervical smears. Tolerability and pharmacokinetics were also assessed. Raloxifene (60 mg per day) was used as a reference. Ospemifene was administered orally in doses of 30, 60 and 90 mg per day. There were 29 volunteers at each dose level, as did the raloxifene group. Ospemifene is given as a gelatin capsule containing 30, 60 or 90 mg of ospemifene. Endometrial thickness was assessed by ultrasonography with a Hitachi EUB-405 instrument. Vaginal epithelium was assessed using the nuclear fragmentation index, an evaluation method well known to those skilled in the art. In this method, the vaginal fraction of the cervical smear is assessed as a percentage of the number of cells in the different layers: ba...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.

Description

[0001] This application is a divisional application of a PCT patent application that entered the Chinese national phase on December 3, 2004, and its Chinese patent application number is 03812878.0, and claims to enjoy the priority on June 6, 2002. technical field [0002] The present invention relates to a method of inhibiting skin, epithelial or mucosal atrophy in women, especially menopausal or postmenopausal women. The invention also relates to the prevention or treatment of symptoms associated with atrophy in women, especially in menopausal or postmenopausal women. Background technique [0003] The publications and other materials are hereby incorporated herein by reference to illustrate the background of the invention and in particular to provide additional details concerning the facts. [0004] During or after menopause, older women often exhibit symptoms due to estrogen deficiency. These symptoms include hot flashes, back sweats, insomnia, depression, vaginal dryness...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/085A61P13/00A61P15/00A61P13/02
CPCA61K31/085A61P13/00A61P13/02A61P15/00A61P15/02A61P15/12A61P17/00A61K31/045
Inventor T·布洛姆P·格伦罗斯K·哈罗宁P·海尔克宁
Owner HORMOS MEDICAL OY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com